LOGIN  |  REGISTER
Terns Pharmaceuticals
Viking Therapeutics

Talkspace Announces First Quarter 2024 Results

May 07, 2024 | Last Trade: US$3.04 0.13 -4.10
  • 1Q 2024 Total revenue grew 36% year-over-year
  • 1Q 2024 Payor revenue grew 92% year-over-year
  • Reduced GAAP Net loss to $1.5 million from $8.8 million year-over-year
  • Delivers first profitable quarter with Adjusted EBITDA1 of $0.8 million

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Talkspace, Inc. (NASDAQ: TALK), today reported first quarter 2024 financial results.

  Three Months
   
Three Months Ended March 31, 2024 (Unaudited) Results % Variance from Prior Year
(In thousands unless otherwise noted)    
Number of eligible lives at period end (in millions)  131.4  34%
Number of completed Payor sessions  284.2  65%
Number of Consumer active members at period end  11.1  (26)%
     
Total revenue  $45,416  36%
Gross profit  $21,731  30%
Gross margin %  47.8%  
Operating expenses  $23,410  (9)%
Net loss  $(1,466)  83%
Adjusted EBITDA1  $774  112%
Cash and cash equivalents at period end  $120,278  
       
(1) Adjusted EBITDA is a non-GAAP financial measure. For a definition of the measure and a reconciliation to the most direct comparable GAAP measure, see “Reconciliation of Non-GAAP Results to GAAP Results.”

Dr. Jon Cohen, CEO of Talkspace, said, “We kicked off 2024 with strong momentum, building on our pivotal achievements from last year. Our first quarter results showcase a 36% year-over-year increase in revenue, driven by our deepening engagement and expanding reach within our Payor category. We also made exciting progress with our recent launches in New York City and the Baltimore County Public School system, two initial clients underpinning our efforts to combat the teen mental health crisis.”

“Importantly, this also marks our first quarter of profitability on an adjusted EBITDA basis. Our cash position, our streamlined operations, and our defined growth strategy give me confidence we are well-equipped to continue advancing our mission to deliver accessible and high-quality mental healthcare. As we continue to scale, our dedication to operational excellence is not only providing greater access to mental healthcare, but also enhancing the quality of care we provide for our members and the experience for our provider network,” added Dr. Cohen.

First Quarter 2024 Key Performance Metrics

  • Revenue increased 36% over the prior-year period to $45.4 million, driven by a 92% year-over-year increase in Payor revenue and a 14% year-over-year increase in Direct to Enterprise (“DTE”) revenue; partially offset by a 29% year-over-year consumer revenue decline.
  • Gross profit increased 30% over the prior-year period to $21.7 million, and gross margin declined to 47.8% from 50.2% year-over-year, driven by a shift in revenue mix towards Payor.
  • Operating expenses were $23.4 million, down 9% year-over-year, driven primarily by efficiencies in Research & Development and Clinical Operations.
  • Net loss was $(1.5) million, an improvement from $(8.8) million net loss in the first quarter of 2023, primarily driven by an increase in revenues and a reduction in operating expenses.
  • Adjusted EBITDA was $0.8 million, an improvement from $(6.4) million in the first quarter of 2023, primarily driven by an increase in revenues and a reduction in operating expenses.

Financial Guidance

Full fiscal year 2024 guidance remains unchanged. Based on current market conditions and expectations and what the Company knows today, Talkspace expects revenue to be in the range of $185 million to $195 million, growth of 23-30%, and adjusted EBITDA to be in the range of $4 million to $8 million.

Conference Call, Presentation Slides, and Webcast Details

The conference call will be available via audio webcast at investors.talkspace.com and can also be accessed by dialing (888) 330-2391 for U.S. participants, or +1 (240) 789-2702 for international participants, and referencing participant code 2348878. A replay will be available shortly after the call’s completion and remain available for approximately 90 days.

About Talkspace

Talkspace (NASDAQ: TALK) is a leading virtual behavioral healthcare provider committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall health and should be available to everyone.

Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services, including therapy for individuals, teens, and couples, as well as psychiatric treatment and medication management (18+). With Talkspace’s core therapy offerings, members are matched with one of thousands of licensed therapists within days and can engage in live video, audio, or chat sessions, and/or unlimited asynchronous text messaging sessions.

All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. More than 131 million Americans have access to Talkspace through their health insurance plans, employee assistance programs, our partnerships with leading healthcare companies, or as a free benefit through their employer, school, or government agency.

For more information, visit www.talkspace.com

For Investors:

ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it. 

For Media:

John Kim
SKDK
(310) 997-5963
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking, including statements regarding our financial condition, anticipated financial performance, achieving profitability, business strategy and plans, market opportunity and expansion and objectives of our management for future operations. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast”, “future”, “intend,” “may,” “might”, “opportunity”, “plan,” “possible”, “potential,” “predict,” “project,” “should,” “strategy”, “strive”, “target,” “will,” or “would”, the negative of these words or other similar terms or expressions. The absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many important factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to factors and the other risks and uncertainties described under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 13, 2024, and our other documents filed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise unless required to do so under applicable law. We do not give any assurance that we will achieve our expectations.

 
Talkspace, Inc.
Condensed Consolidated Statements of Operations
 
 Three Months Ended
March 31,
  
 2024 2023 % Change
(in thousands, except percentages, share and per share data)Unaudited Unaudited  
Revenue:     
Payor revenue$28,508 $14,811 92.5
DTE revenue9,913 8,676 14.3
Consumer revenue6,995 9,849 (29.0)
Total revenue45,416 33,336 36.2
Cost of revenues23,685 16,588 42.8
Gross profit21,731 16,748 29.8
Operating expenses:     
Research and development3,739 5,353 (30.2)
Clinical operations, net1,464 1,601 (8.6)
Sales and marketing13,009 13,469 (3.4)
General and administrative5,198 5,364 (3.1)
Total operating expenses23,410 25,787 (9.2)
Operating loss(1,679) (9,039) 81.4
Financial (income), net(378) (424) (10.8)
Loss before taxes on income(1,301) (8,615) 84.9
Taxes on income165 143 15.4
Net loss$(1,466) $(8,758) 83.3
Net loss per share:     
Basic and Diluted$(0.01) $(0.05) 80.0
Weighted average number of common shares:     
Basic and Diluted168,846,946 161,797,781  

 

 
Talkspace, Inc.
Condensed Consolidated Balance Sheets
   
 March 31, 2024  December 31, 2023 
(in thousands)Unaudited    
ASSETS     
CURRENT ASSETS:     
Cash and cash equivalents$120,278  $123,908 
Accounts receivable 11,035   10,174 
Other current assets 4,417   5,718 
Total current assets 135,730   139,800 
Other long-term assets 2,546   2,421 
Total assets$138,276  $142,221 
LIABILITIES AND STOCKHOLDERS’ EQUITY     
CURRENT LIABILITIES:     
Accounts payable$5,805  $6,111 
Deferred revenues 2,883   3,069 
Accrued expenses and other current liabilities 6,998   12,468 
Total current liabilities 15,686   21,648 
Warrant liabilities 2,988   1,842 
Other liabilities 24   85 
Total liabilities 18,698   23,575 
STOCKHOLDERS’ EQUITY:     
Common stock 16   16 
Additional paid-in capital 391,412   389,014 
Accumulated deficit (271,850)  (270,384)
Total stockholders’ equity 119,578   118,646 
Total liabilities and stockholders’ equity$138,276  $142,221 

 

 
Talkspace, Inc.
Condensed Consolidated Statements of Cash Flows
 
 Three Months Ended
March 31,
 
 2024  2023 
(in thousands)Unaudited  Unaudited 
Cash flows from operating activities:     
Net loss$(1,466) $(8,758)
Adjustments to reconcile net loss to net cash used in operating activities:     
Depreciation and amortization 201   306 
Stock-based compensation 2,252   2,303 
Remeasurement of warrant liabilities 1,146   189 
Increase in accounts receivable (861)  (2,820)
Decrease in other current assets 1,301   559 
(Decrease) increase in accounts payable (306)  1,213 
Decrease in deferred revenues (186)  (232)
Decrease increase in accrued expenses and other current liabilities (5,470)  (6,702)
Other (2)  (95)
Net cash used in operating activities (3,391)  (14,037)
Cash flows from investing activities:     
Purchase of property and equipment (385)  (9)
Proceeds from sale of property and equipment    28 
Net cash used in investing activities (385)  19 
Cash flows from financing activities:     
Proceeds from exercise of stock options 741   621 
Payments for employee taxes withheld related to vested stock-based awards (595)  (65)
Net cash provided by financing activities 146   556 
Net decrease in cash and cash equivalents (3,630)  (13,462)
Cash and cash equivalents at the beginning of the period 123,908   138,545 
Cash and cash equivalents at the end of the period$120,278  $125,083 

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance, and our management uses it as a key performance measure to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities. We also use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. We believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP.

Some of the limitations of adjusted EBITDA include (i) adjusted EBITDA does not necessarily reflect capital commitments to be paid in the future and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these requirements. In evaluating adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments described herein. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. Our adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure. Adjusted EBITDA should not be considered as an alternative to loss before income taxes, net loss, loss per share, or any other performance measures derived in accordance with U.S. GAAP. When evaluating our performance, you should consider adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.

A reconciliation is provided below for adjusted EBITDA to net loss, the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review our financial statements prepared in accordance with GAAP and the reconciliation of our non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business. We do not provide a forward-looking reconciliation of adjusted EBITDA guidance as the amount and significance of the reconciling items required to develop meaningful comparable GAAP financial measures cannot be estimated at this time without unreasonable efforts. These reconciling items could be meaningful.

Adjusted EBITDA

We calculate adjusted EBITDA as net loss adjusted to exclude (i) depreciation and amortization, (ii) interest and other expenses (income), net, (iii) tax benefit and expense, and (iv) stock-based compensation expense.

 
Talkspace, Inc.
Reconciliation of Non-GAAP Results to GAAP Results
 
 Three Months Ended
March 31,
 
 2024  2023 
(in thousands)Unaudited  Unaudited 
Net loss$(1,466) $(8,758)
Add:     
Depreciation and amortization 201   306 
Financial (income), net (1) (378)  (424)
Taxes on income 165   143 
Stock-based compensation 2,252   2,303 
Adjusted EBITDA$774  $(6,430)
(1)For the three months ended March 31, 2024, financial (income), net, primarily consisted of $1.6 million of interest income from our money market accounts partially offset by $1.1 million in losses resulting from the remeasurement of warrant liabilities. For the three months ended March 31, 2023, financial (income), net, primarily consisted of $0.6 million of interest income from our money market accounts partially offset by $0.2 million in losses resulting from the remeasurement of warrant liabilities

C4 Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB